The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition

PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for the treatment of high-grade serous ovarian cancers (HGSOCs). Therapeutic resistance, resulting from restoration of homologous recombination (HR) repair or replication fork stabilization, is a pressing clinical problem. We asses...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Parmar, Kalindi, Kochupurakkal, Bose S., Lazaro, Jean-Bernard, Wang, Zhigang C., Palakurthi, Sangeetha, Kirschmeier, Paul T., Yang, Chunyu, Sambel, Larissa A., Farkkila, Anniina, Reznichenko, Elizaveta, Reavis, Hunter D, Dunn, Connor E., Zou, Lee, Do, Khanh T., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Liu, Joyce F., D’Andrea, Alan D., Shapiro, Geoffrey I.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6801076/
https://ncbi.nlm.nih.gov/pubmed/31409614
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0448
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi